241 related articles for article (PubMed ID: 34328274)
21.
Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
Front Immunol; 2021; 12():677169. PubMed ID: 34354701
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
23. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of the immunogenicity and tumor immune microenvironment in
Wang Q; Mao Z; Li W; Wang S; Wang L; Chen L; Yang Z; Fu X; Jiang P; Bai Y; Xu L; Zhang S; Hou Y; Jia X; Jiang L; Liu M; Zhang G; Jiang Y; Guo H
Front Immunol; 2022; 13():1042072. PubMed ID: 36591290
[TBL] [Abstract][Full Text] [Related]
25. Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes.
Isaeva OI; Sharonov GV; Serebrovskaya EO; Turchaninova MA; Zaretsky AR; Shugay M; Chudakov DM
J Immunother Cancer; 2019 Oct; 7(1):279. PubMed ID: 31665076
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
[TBL] [Abstract][Full Text] [Related]
28. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
[TBL] [Abstract][Full Text] [Related]
29. EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.
Chen Z; Chen J; Ren D; Zhang J; Yang Y; Zhang H; Mao B; Ma H
Aging (Albany NY); 2020 Dec; 13(1):598-618. PubMed ID: 33288738
[TBL] [Abstract][Full Text] [Related]
30. Immune profile of the tumor microenvironment and the identification of a four-gene signature for lung adenocarcinoma.
Fan T; Zhu M; Wang L; Liu Y; Tian H; Zheng Y; Tan F; Sun N; Li C; He J
Aging (Albany NY); 2020 Dec; 13(2):2397-2417. PubMed ID: 33318300
[TBL] [Abstract][Full Text] [Related]
31. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
Front Immunol; 2021; 12():723172. PubMed ID: 34539658
[TBL] [Abstract][Full Text] [Related]
32. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract][Full Text] [Related]
33. Prognostic model of lung adenocarcinoma constructed by the CENPA complex genes is closely related to immune infiltration.
Zhou H; Bian T; Qian L; Zhao C; Zhang W; Zheng M; Zhou H; Liu L; Sun H; Li X; Zhang J; Liu Y
Pathol Res Pract; 2021 Dec; 228():153680. PubMed ID: 34798483
[TBL] [Abstract][Full Text] [Related]
34. Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma.
Behrens C; Rocha P; Parra ER; Feng L; Rodriguez-Canales J; Solis LM; Mino B; Zhang J; Gibbons DL; Sepesi B; Rice D; Heymach JV; Moran C; Creighton CJ; Lee JJ; Kadara H; Wistuba II
Clin Lung Cancer; 2021 May; 22(3):e415-e424. PubMed ID: 32763065
[TBL] [Abstract][Full Text] [Related]
35. Novel immune subtypes of lung adenocarcinoma identified through bioinformatic analysis.
Qin FL; Xu ZY; Yuan LQ; Chen WJ; Wei JB; Sun Y; Li SK
FEBS Open Bio; 2020 Sep; 10(9):1921-1933. PubMed ID: 32686362
[TBL] [Abstract][Full Text] [Related]
36. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
37. Identification immunophenotyping of lung adenocarcinomas based on the tumor microenvironment.
Tan Q; Huang Y; Deng K; Lu M; Wang L; Rong Z; Zhao W; Li S; Xu Z; Fan L; Li K; Li Z
J Cell Biochem; 2020 Nov; 121(11):4569-4579. PubMed ID: 32030808
[TBL] [Abstract][Full Text] [Related]
38. Machine learning reveals two heterogeneous subtypes to assist immune therapy based on lipid metabolism in lung adenocarcinoma.
Gu X; Wei S; Li Z; Xu H
Front Immunol; 2022; 13():1022149. PubMed ID: 36238302
[TBL] [Abstract][Full Text] [Related]
39. EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion.
Marzio A; Kurz E; Sahni JM; Di Feo G; Puccini J; Jiang S; Hirsch CA; Arbini AA; Wu WL; Pass HI; Bar-Sagi D; Papagiannakopoulos T; Pagano M
Cell; 2022 Jan; 185(1):169-183.e19. PubMed ID: 34963055
[TBL] [Abstract][Full Text] [Related]
40. NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
Xu X; Yang Y; Liu X; Cao N; Zhang P; Zhao S; Chen D; Li L; He Y; Dong X; Wang K; Lin H; Mao N; Liu L
Oncologist; 2020 Jun; 25(6):e955-e963. PubMed ID: 32272498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
